News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Adeona Pharmaceuticals (AEN) and National Neurovision Research Institute (NNRI) Collaborate to Test Flupirtine for Retinitis Pigmentosa


12/2/2008 8:32:52 AM

ANN ARBOR, MI and OWINGS MILLS, MD--(Marketwire - December 02, 2008) - National Neurovision Research Institute (NNRI), a research support organization for the Foundation Fighting Blindness, the leading non-government funding source for inherited orphan retinal degeneration research and Adeona Pharmaceuticals, Inc. (AMEX: AEN) announced today a research collaboration whereby NNRI will fully fund preclinical studies to evaluate the potential of flupirtine for the treatment of retinitis pigmentosa (RP), a blinding eye disease that currently lacks an FDA approved treatment.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES